Recently, research advances have increased our understanding of the pathogenesis of the most common inflammatory chronic skin diseases such as psoriasis, hidradenitis suppurativa and atopic dermatitis, which lead to the development of highly safe and effective targeted innovative treatments. Biologic drugs (chimeric, humanized, and fully human monoclonal antibodies), biosimilars, and small molecules, have completely transformed the management of chronic inflammatory skin diseases.
Precision medicine may guide future pharmacogenomics and genetic studies in order to identify biomarkers that can help clinicians predict disease progression and/or treatment response, resulting in the performance of an evidence-based treatment selection to ensure the right treatment for the right patient at the right time. Hence, over clinical trials, real-life data may improve the knowledge of the newest available targeted therapies, increasing the knowledge of these drugs also in the daily clinical practice
This Research Topic will welcome papers which aim collate the most up-to-date scientific research on chronic inflammatory skin disease treatment, with a focus on:
- New or relevant adverse effects, and their management
- Pharmacovigilance and pharmacoepidemiology data
- Post-marketing surveillance
- Real life data about safety and efficacy profiles
- Individual drugs and drug classes
- Recent or emerging advancements in the management of chronic skin diseases.
Recently, research advances have increased our understanding of the pathogenesis of the most common inflammatory chronic skin diseases such as psoriasis, hidradenitis suppurativa and atopic dermatitis, which lead to the development of highly safe and effective targeted innovative treatments. Biologic drugs (chimeric, humanized, and fully human monoclonal antibodies), biosimilars, and small molecules, have completely transformed the management of chronic inflammatory skin diseases.
Precision medicine may guide future pharmacogenomics and genetic studies in order to identify biomarkers that can help clinicians predict disease progression and/or treatment response, resulting in the performance of an evidence-based treatment selection to ensure the right treatment for the right patient at the right time. Hence, over clinical trials, real-life data may improve the knowledge of the newest available targeted therapies, increasing the knowledge of these drugs also in the daily clinical practice
This Research Topic will welcome papers which aim collate the most up-to-date scientific research on chronic inflammatory skin disease treatment, with a focus on:
- New or relevant adverse effects, and their management
- Pharmacovigilance and pharmacoepidemiology data
- Post-marketing surveillance
- Real life data about safety and efficacy profiles
- Individual drugs and drug classes
- Recent or emerging advancements in the management of chronic skin diseases.